Publication: Melatonin Attenuates High Glucose-Induced Changes in Beta Amyloid Precursor Protein Processing in Human Neuroblastoma Cells
2
Issued Date
2021-01-01
Resource Type
ISSN
15736903
03643190
03643190
Other identifier(s)
2-s2.0-85102382826
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Neurochemical Research. (2021)
Suggested Citation
Chutikorn Nopparat, Worawut Chaopae, Parichart Boontem, Pattarawut Sopha, Prapimpun Wongchitrat, Piyarat Govitrapong Melatonin Attenuates High Glucose-Induced Changes in Beta Amyloid Precursor Protein Processing in Human Neuroblastoma Cells. Neurochemical Research. (2021). doi:10.1007/s11064-021-03290-5 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/76401
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Melatonin Attenuates High Glucose-Induced Changes in Beta Amyloid Precursor Protein Processing in Human Neuroblastoma Cells
Other Contributor(s)
Abstract
Diabetes mellitus (DM), one of metabolic diseases, has been suggested as a risk factor for Alzheimer’s disease (AD). However, how the metabolic pathway activates amyloid precursor protein (APP) processing enzymes then contributes to the increase of amyloid-beta (Aβ) production, is not clearly understood. In the present study, we aimed to examine the protective effect of melatonin against hyperglycemia-induced alterations in the amyloidogenic pathway. High concentration of glucose was used to induce hyperglycemia in human neuroblastoma SH-SY5Y cells. We found that 30 mM glucose affected the expression of insulin receptors and glucose transporters, which indicated the disruption of glucose sensing. High glucose induced the activation of the phosphorylated protein kinase B (pAkt)/GSK-3β signaling pathway and a significant increase in the expression of β-site beta APP cleaving enzyme (BACE1), presenilin1 (PS1) and Aβ42. Pretreatment with melatonin significantly reversed these parameters. We also showed that these effects are similar to those effects in the presence of the GSK-3β blocker, N-(4-methoxybenyl)-N′-(5-nitro-1,3-thiazol-2-yl) urea (ARA) in glucose-treated hyperglycemic cells. These suggested that melatonin exerted an inhibitory effect on the activation of APP-cleaving enzymes via the GSK-3β signaling pathway. Pretreatment with luzindole, a melatonin receptor MT1 antagonist, significantly prevented the effect of melatonin on the glucose-induced increase level of APP processing enzymes. This suggested that melatonin attenuated the toxic effect on hyperglycemia involving the amyloidogenic pathway partially mediated via melatonin receptor. Taken together the present results suggested that melatonin has a beneficial role in preventing Aβ generation in a cellular model of hyperglycemia-induced DM.